Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 09, 2024

SELL
$0.28 - $0.64 $3,242 - $7,412
-11,582 Reduced 85.27%
2,000 $1,000
Q3 2023

Nov 09, 2023

BUY
$0.29 - $0.48 $1,034 - $1,712
3,567 Added 35.62%
13,582 $4,000
Q2 2023

Aug 11, 2023

BUY
$0.28 - $0.79 $1,668 - $4,708
5,960 Added 146.98%
10,015 $3,000
Q1 2023

May 12, 2023

SELL
$0.63 - $1.3 $444 - $916
-705 Reduced 14.81%
4,055 $3,000
Q4 2022

Feb 08, 2023

SELL
$0.86 - $22.2 $10,212 - $263,625
-11,875 Reduced 71.39%
4,760 $4,000
Q3 2022

Nov 10, 2022

SELL
$0.83 - $17.8 $124,220 - $2.66 Million
-149,663 Reduced 90.0%
16,635 $15,000
Q2 2022

Aug 10, 2022

BUY
$0.7 - $1.56 $108,509 - $241,821
155,014 Added 1373.75%
166,298 $184,000
Q1 2022

May 16, 2022

SELL
$1.37 - $2.43 $18,499 - $32,812
-13,503 Reduced 54.48%
11,284 $16,000
Q4 2021

Feb 14, 2022

SELL
$2.27 - $4.39 $320,769 - $620,342
-141,308 Reduced 85.08%
24,787 $56,000
Q3 2021

Nov 15, 2021

BUY
$3.37 - $4.76 $79,697 - $112,569
23,649 Added 16.6%
166,095 $692,000
Q2 2021

Aug 13, 2021

BUY
$4.75 - $9.39 $661,005 - $1.31 Million
139,159 Added 4233.62%
142,446 $677,000
Q1 2021

May 12, 2021

BUY
$4.59 - $9.04 $15,087 - $29,714
3,287 New
3,287 $27,000
Q4 2020

Feb 11, 2021

SELL
$1.51 - $6.3 $5,831 - $24,330
-3,862 Closed
0 $0
Q3 2020

Nov 12, 2020

BUY
$1.7 - $3.28 $6,565 - $12,667
3,862 New
3,862 $7,000
Q2 2020

Jul 31, 2020

SELL
$2.43 - $3.23 $243 - $323
-100 Closed
0 $0
Q1 2020

May 01, 2020

SELL
$2.49 - $4.39 $776 - $1,369
-312 Reduced 75.73%
100 $0
Q4 2019

Feb 14, 2020

SELL
$3.75 - $6.11 $4,548 - $7,411
-1,213 Reduced 74.65%
412 $1,000
Q3 2019

Nov 14, 2019

SELL
$3.87 - $6.13 $808 - $1,281
-209 Reduced 11.4%
1,625 $8,000
Q2 2019

Aug 14, 2019

BUY
$4.86 - $9.24 $8,913 - $16,946
1,834 New
1,834 $13,000

Others Institutions Holding ONCT

About Oncternal Therapeutics, Inc.


  • Ticker ONCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,517,200
  • Market Cap $29.4M
  • Description
  • Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a smal...
More about ONCT
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.